Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [2] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for many patients [2] - The inclusion of Lenvatinib in the insurance list allows treatment for both Langerhans cell histiocytosis and neurofibromatosis type I in children aged 2 and above, expanding access compared to previous medications [4] Group 2 - The national medical insurance has covered over 50 rare disease types, but there remains a gap compared to the 207 rare diseases listed, due to high costs and lack of available treatments [4] - The introduction of commercial insurance for innovative drugs includes 19 medications, including Lenvatinib, allowing for discounted pricing and reducing the financial burden on families [7] - Initiatives such as the publication of clinical guidelines for 86 rare diseases and the establishment of a national rare disease diagnosis and treatment network are enhancing support for patients [7]

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [1][3] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for most patients [1][3] - The inclusion of Lenvatinib in the insurance list not only treats Langerhans cell histiocytosis but also extends to pediatric patients with neurofibromatosis type I, lowering the age limit for treatment from 3 years to 2 years [3][4] Group 2 - The national medical insurance has included 19 innovative drugs, including 6 rare disease medications, in a new commercial insurance model to improve accessibility [4] - Measures such as the publication of clinical guidelines for 86 rare disease types and the establishment of a national rare disease diagnosis and treatment collaboration network are being implemented to enhance patient care [4][5] - The combination of policy support and community initiatives, such as the "Little Cat Cheer Up" app for parents of rare disease children, is fostering a supportive environment for patients [4][5]

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [1] - The inclusion of the drug Lenvatinib for Langerhans cell histiocytosis in the insurance list is significant, as it also treats neurofibromatosis type I in children aged 2 and above, expanding access compared to previous coverage [1] - Currently, the insurance covers over 50 rare disease types, but there is still a gap compared to the 207 rare diseases listed, due to some diseases lacking effective treatments and the high costs of certain medications [1] Group 2 - The introduction of commercial insurance for innovative drug coverage includes 19 drugs, such as the expensive medication for neuroblastoma, which previously cost hundreds of thousands of yuan per treatment [2] - The measures taken, including the establishment of diagnostic guidelines for 86 rare diseases and a green channel for drug review and approval, aim to strengthen life protection for rare disease patients [2] - A small program created by a parent of a rare disease patient has facilitated communication among over 5,800 families, showcasing community support and shared experiences [2]

Group 1 - The number of rare disease medications in China's medical insurance list has exceeded 100, covering over 50 types of diseases, marking a new high and providing hope for more patients [1][2] - The inclusion of the drug Lenvatinib for Langerhans cell histiocytosis in the national medical insurance list is significant, as it not only treats this condition but also extends its use to children and adolescents with neurofibromatosis type I [1] - The medical insurance currently covers over 50 rare disease types, but there is still a gap compared to the 207 rare disease types listed, due to some diseases lacking effective treatments and the high costs of certain medications [2] Group 2 - The introduction of commercial insurance for innovative drug listings by the National Medical Insurance Administration aims to improve access to rare disease medications, including the high-cost drug Daratumumab for neuroblastoma, which previously had a treatment cost in the hundreds of thousands [3] - Various initiatives, such as the publication of clinical guidelines for 86 rare disease types and the establishment of a national collaborative network for rare disease diagnosis and treatment, are enhancing life security for patients [3] - The combination of policy support and community efforts is fostering a more hopeful environment for rare disease patients, encouraging collaboration among families and sharing of experiences [4]

Investment Rating - The report initiates coverage with an OUTPERFORM rating for BeiGene [2]. Core Views - BeiGene is positioned as a leading innovator in China's biopharmaceutical sector, with a strong focus on oncology treatments and a robust pipeline of over 60 clinical projects globally [3][11]. - The company is expected to achieve profitability by 2025, driven by significant revenue growth from its core products, particularly the BTK inhibitor, Zanubrutinib, which is projected to double its revenue in 2024 [4][20]. - BeiGene's global commercialization capabilities and a well-established management team are key competitive advantages that will support its growth trajectory [12][29]. Summary by Sections 1. Innovative Product Globalization - BeiGene has a diverse product pipeline and aims to become the first biopharma company to achieve consistent profitability [11]. - The company has 17 commercialized products, including Zanubrutinib and Tislelizumab, with strong sales performance in the US and Europe [20]. - Revenue for 2024 is projected at $3.81 billion, a 55% increase year-over-year, with significant contributions from the US market [20]. 2. Leadership in Hematology - The combination of BTK inhibitors and BCL-2 inhibitors is expected to solidify BeiGene's leadership in hematological malignancies [5]. - Zanubrutinib has shown superior efficacy compared to Ibrutinib, establishing its best-in-class status [5][24]. - The company is also developing Sonratoclax, a BCL-2 inhibitor, which is anticipated to enhance its market position [5]. 3. Expansion in Solid Tumors - BeiGene is actively expanding its presence in solid tumors, with Tislelizumab gaining traction in various indications [11]. - The company is developing next-generation CDK inhibitors targeting a market exceeding $10 billion [11]. - Focus areas include lung cancer and breast cancer, with ongoing clinical trials for multiple candidates [11]. 4. Financial Projections and Valuation - Revenue forecasts for FY25-27 are $5 billion, $6 billion, and $6.7 billion, respectively, with a CAGR of 21% [7]. - The net profit is expected to turn positive by FY25, reaching $390 million by FY26 [7]. - The target price is set at HK$182.35, based on a DCF model with a WACC of 9% and a perpetual growth rate of 4% [7].